Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price rose 25.6% during trading on Thursday . The company traded as high as C$0.29 and last traded at C$0.27. Approximately 1,058,771 shares changed hands during trading, an increase of 65% from the average daily volume of 640,063 shares. The stock had previously closed at C$0.22.
Hemostemix Price Performance
The company has a 50-day moving average price of C$0.10 and a 200 day moving average price of C$0.08. The firm has a market capitalization of C$23.52 million, a PE ratio of -13.50 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- What Does Downgrade Mean in Investing?
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
